Objectives: The present study aimed to examine the impact of rapid virological response (RVR) and early virological response (EVR) on sustained virological response (SVR) in chronic hepatitis C genotype 3a individuals. Methods: The patients were given antiviral therapy with IFN-α-2b, 3 million units 3 times a week and 800-1,200 mg of ribavirin daily adjusted to the patient's body weight (<60 kg 800 mg day−1, and >60 kg 1,200 day−1). The patients received this combination therapy for 24 weeks. The patients were evaluated for their viral load at week 4, 12, and 24 using RT-PCR. Results: Out of 1,471 patients, 43.3% showed a negative viral load in week 4, demonstrating RVR, whereas 56.6% maintained a high viral load. These were further separated based on viral reduction in their plasma: either negative for HCV-RNA at week 12 (n = 575), manifesting EVR, or showing a 2-log reduction in HCV viral load classified as partial EVR (PEVR; n = 259). The PEVR response was less (29.7%) compared with RVR (85.9%) and EVR (69.0%), although nonresponders were found in both groups. Conclusions: Individuals incompliant with their treatment who have a higher RVR significantly influence their SVR towards a better remission that can be treated within a short duration with standard treatment.

Keywords:
Ribavirin, Antiviral therapy, Hepatitis C virus, Interferon-α-2b, Sustained virological response, Viral load
1.
Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-567.
2.
Robertson B, Myers G, Howard C, et al: Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch Virol 1998;143:2493-2503.
3.
Akhtar N, Bilal M, Rizwan M, et al: Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan. Asian Pac J Cancer Prev 2014;16:1037-1040.
4.
Ilyas M, Ahmad I: Chemiluminescent microparticle immunoassay based detection and prevalence of HCV infection in district Peshawar, Pakistan. Virol J 2014;11:127.
5.
Ahmad I: Prevalence of hepatitis B and C viral infection among pregnant women in Peshawar, Pakistan. Hepat Mon 2016;16:e36383.
6.
Bari A, Akhtar S, Rahbar MH, et al: Risk factors for hepatitis C virus infection in male adults in Rawalpindi-Islamabad, Pakistan. Trop Med Int Health 2001;6:732-738.
7.
Kim WR: Global epidemiology and burden of hepatitis C. Microbes Infect 2002;4:1219-1225.
8.
Waheed Y, Safi SZ, Qadri I: Role of potash alum in hepatitis C virus transmission at barber's shop. Virol J 2011;8:211.
9.
Zeuzem S, Hultcrantz R, Bourliere M, et al: Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-999.
10.
Stuyver L, Rossau R, Wyseur A, et al: Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-1102.
11.
Simmonds P, McOmish F, Yap P, et al: Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 1993;74:661-668.
12.
Akhtar S, Moatter T, Azam S, et al: Prevalence and risk factors for intrafamilial transmission of hepatitis C virus in Karachi, Pakistan. J Viral Hepat 2002;9:309-314.
13.
Khokhar N: Treatment of interferon non-responsive chronic hepatitis C with triple therapy with interferon, ribavirin, and amantidine can be encouraging. Gut 2004;53:468-469.
14.
Liang TJ: Combination therapy for hepatitis C infection. New Engl J Med 1998;339:1549-1550.
15.
Reichert T, et al: Randomised, double blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-87.
16.
Raza H, Ahmad T, Afzal M: HCV, interferon therapy response, direct acting antiviral therapy revolution and Pakistan: future perspectives. Asian Pac J Cancer Prev 2014;16:5583-5584.
17.
Arshad BG, Raza A, Aziz H, et al: Genetic, biochemical, and immunological determinants of viral resistance to interferon alpha 2b combination therapy of HCV 3a infected Pakistani patients. Life Sci J 2013;10:3225-3233.
18.
Aziz H, Raza A, Murtaza S, et al: Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Punjab Province in Pakistan and a phylogenetic analysis. Int J Inf Dis 2013;17:e247-e253.
19.
Keyvani H, Fazlalipour M, Monavari SHR, et al: Hepatitis C virus-proteins, diagnosis, treatment and new approaches for vaccine development. Asian Pac J Cancer Prev 2012;13:5917-5935.
20.
Aziz H, Gil ML, Waheed Y, et al: Evaluation of prognostic factors for Peg interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. Infect Genet Evol 2011;11:640-645.
21.
Ali S, Ahmad A, Khan RS, et al: Genotyping of HCV RNA reveals that 3a is the most prevalent genotype in Mardan, Pakistan. Adv Virol 2014;2014:606201.
22.
Ghany MG, Strader DB, Thomas DL, et al: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
23.
Raza A, Ali Z, Irfan J, et al: Analytical variables influencing the HCV RNA determination by TaqMan real-time PCR in routine clinical laboratory practice. Mol Biol Rep 2012;39:7421-7427.
24.
Shah HA, Jafri W, Malik I, et al: Hepatitis C virus (HCV) genotypes and chronic liver disease in Pakistan. J Gastroenterol Hepatol 1997;12:758-761.
25.
Moatter T, Hussainy AS, Hamid S, et al: Comparative analysis of viral titers and histologic features of Pakistani patients infected with hepatitis C virus type 3. Int J Inf Dis 2002;6:272-276.
26.
Azhar M, Bukhari M, Ghanni U, et al: Prevalence of hepatitis C virus and its serotypes in Bahawalpur Division. Biomedica 2003;19:18-22.
27.
Khokhar N, Asif N, Khokhar OS: Serotype 3 is most common hepatitis C serotype in Pakistan: however, significant numbers are untypeable. Hepatology 2003;38:270-271.
28.
Ahmad N, Asgher M, Shafique M, et al: An evidence of high prevalence of hepatitis C virus in Faisalabad, Pakistan. Saudi Med J 2007;28:390-395.
29.
Afridi S, Naeem M, Hussain A, et al: Prevalence of hepatitis C virus (HCV) genotypes in Balochistan. Mol Biol Rep 2009;36:1511-1514.
30.
Ali M, Afzal S, Zia A, et al: A systematic review of treatment response rates in Pakistani hepatitis C virus patients; current prospects and future challenges. Medicine 2016;95:50.
31.
Ohno O, Mizokami M, Wu R-R, et al: New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997;35:201-207.
32.
National Institutes of Health: National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002;36:S3-S20.
33.
Buster E, van Erpecum K, Schalm S, et al: Netherlands Association of Gastroenterologists and Hepatologists: treatment of chronic hepatitis B virus infection - Dutch national guidelines. Neth J Med 2008;66:292-306.
34.
Stroffolini T, Rapicetta M, Di Stefano R: Hepatitis C virus clearance and gender. Gut 2007;56:884.
35.
Idrees M, Riazuddin S: A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 2009;9:1.
36.
Shiffman ML, Suter F, Bacon BR, et al: Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. New Engl J Med 2007;357:124-134.
37.
Berg T, von Wagner M, Nasser S, et al: Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-1097.
38.
Sánchez-Tapias JM, Diago M, Escartín P, et al: Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006;131:451-460.
39.
Pearlman BL: Chronic hepatitis C therapy: changing the rules of duration. Clin Gastroenterol Hepatol 2006;4:963-971.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.